PDF(Pubmed)
Abstract：
To perform a systematic review to describe the available findings on clinical outcomes in HIV-1 and HTLV-1/HTLV-2 co-infected individuals since 1995.
This Systematic Review used PECO criteria follow by PRISMA reporting guidelines and registered as CRD42021279062 (Prospero database). The Newcastle-Ottawa Scale assessed the methodological quality of included studies.
A systematical search in PubMed/MEDLINE, Embase, Web of Sciences databases for cross-sectional, case-control, or cohort studies design to identify clinical and laboratorial outcomes related to HIV-1 and HTLV-1/2 coinfection. Search strategy: [(\"HIV-1\" AND \"HTLV-1\" OR \"HTLV-2\") AND (\"Coinfection\") AND (1990/01/01:2021/12/31[Date- Publication])].
A total of 15 articles were included on this systematic review describing data of 2,566 mono and coinfected patients, 58% male, with mean age was 35.7 ± 5.7 years. HIV-1 and HTLV-1 coinfected patients were more likely to had shorter survival and faster progression to death or mortality than monoinfected ones. Coinfected had higher CD4 cell counts and less likelihood of ART use. In addition, higher frequency of diseases like ichthyosis (22.2 vs. 6.8%), scabies (18.6 vs. 0%), candidiasis (42 vs. 12%), Strongyloidiasis (15.4 vs. 2%) and neurological manifestations like encephalopathy, peripheral neuropathy and HAM/TSP were more frequently reported in coinfected patients.
HIV-1 and HTLV-1 coinfection and HIV-1 and HTLV-1 /2 triple coinfection were related to shorter survival, higher mortality rate, and faster progression to death, while coinfection by HIV-1/HTLV-2 seems to have neutral association with longer survival, slower AIDS progression, and lower mortality rate. The available evidence indicates an urgent need for prevention and control measures, including screening, diagnosis, and treatment of HIV-1 and HTLV-1/2 coinfected patients. Test-and-treat strategy for patients living with HIV in areas endemic for HTLV infection is mandatory, to avoid the risks of delayed therapy and death for coinfected patients.
https://www.crd.york.ac.uk/prospero/, identifier: CRD42021279062.
This Systematic Review used PECO criteria follow by PRISMA reporting guidelines and registered as CRD42021279062 (Prospero database). The Newcastle-Ottawa Scale assessed the methodological quality of included studies.
A systematical search in PubMed/MEDLINE, Embase, Web of Sciences databases for cross-sectional, case-control, or cohort studies design to identify clinical and laboratorial outcomes related to HIV-1 and HTLV-1/2 coinfection. Search strategy: [(\"HIV-1\" AND \"HTLV-1\" OR \"HTLV-2\") AND (\"Coinfection\") AND (1990/01/01:2021/12/31[Date- Publication])].
A total of 15 articles were included on this systematic review describing data of 2,566 mono and coinfected patients, 58% male, with mean age was 35.7 ± 5.7 years. HIV-1 and HTLV-1 coinfected patients were more likely to had shorter survival and faster progression to death or mortality than monoinfected ones. Coinfected had higher CD4 cell counts and less likelihood of ART use. In addition, higher frequency of diseases like ichthyosis (22.2 vs. 6.8%), scabies (18.6 vs. 0%), candidiasis (42 vs. 12%), Strongyloidiasis (15.4 vs. 2%) and neurological manifestations like encephalopathy, peripheral neuropathy and HAM/TSP were more frequently reported in coinfected patients.
HIV-1 and HTLV-1 coinfection and HIV-1 and HTLV-1 /2 triple coinfection were related to shorter survival, higher mortality rate, and faster progression to death, while coinfection by HIV-1/HTLV-2 seems to have neutral association with longer survival, slower AIDS progression, and lower mortality rate. The available evidence indicates an urgent need for prevention and control measures, including screening, diagnosis, and treatment of HIV-1 and HTLV-1/2 coinfected patients. Test-and-treat strategy for patients living with HIV in areas endemic for HTLV infection is mandatory, to avoid the risks of delayed therapy and death for coinfected patients.
https://www.crd.york.ac.uk/prospero/, identifier: CRD42021279062.
摘要：
进行系统评价，以描述自1995年以来HIV-1和HTLV-1/HTLV-2共感染个体的临床结果。
本系统评价使用PRISMA报告指南遵循的PECO标准，并注册为CRD42021279062（Prospero数据库）。纽卡斯尔-渥太华量表评估了纳入研究的方法学质量。
PubMed/MEDLINE中的系统搜索，Embase,用于横截面的WebofSciences数据库，病例控制，或队列研究设计，以确定与HIV-1和HTLV-1/2合并感染相关的临床和实验室结局。搜索策略：[（\"HIV-1\"和\"HTLV-1\"或\"HTLV-2\"）和（\"共感染\"）和（1990/01/01：2021/12/31[日期-出版物]）]。
本系统综述共纳入15篇文章，描述了2,566例单感染和合并感染患者的数据。58%男性,平均年龄为35.7±5.7岁。与单一感染的患者相比，HIV-1和HTLV-1合并感染的患者更可能具有更短的生存期和更快的死亡或死亡率进展。合并感染的CD4细胞计数较高，使用ART的可能性较小。此外,鱼鳞病等疾病的发病率较高(22.2vs.6.8%），sc疮（18.6vs.0%)，念珠菌病（42vs.12%），网虫病（15.4vs.2％）和脑病等神经系统表现，合并感染患者中周围神经病变和HAM/TSP的报告频率更高.
HIV-1和HTLV-1共感染以及HIV-1和HTLV-1/2三重共感染与较短的生存期有关，死亡率更高，更快的死亡进程，而合并感染HIV-1/HTLV-2似乎与更长的生存期有中性关联，艾滋病进展较慢，和较低的死亡率。现有证据表明，迫切需要预防和控制措施，包括筛查,诊断,以及HIV-1和HTLV-1/2共感染患者的治疗。在HTLV感染流行地区，HIV感染者的检测和治疗策略是强制性的，避免合并感染患者延迟治疗和死亡的风险。
https://www。crd.约克。AC.英国/普华永道/，标识符：CRD42021279062。
本系统评价使用PRISMA报告指南遵循的PECO标准，并注册为CRD42021279062（Prospero数据库）。纽卡斯尔-渥太华量表评估了纳入研究的方法学质量。
PubMed/MEDLINE中的系统搜索，Embase,用于横截面的WebofSciences数据库，病例控制，或队列研究设计，以确定与HIV-1和HTLV-1/2合并感染相关的临床和实验室结局。搜索策略：[（\"HIV-1\"和\"HTLV-1\"或\"HTLV-2\"）和（\"共感染\"）和（1990/01/01：2021/12/31[日期-出版物]）]。
本系统综述共纳入15篇文章，描述了2,566例单感染和合并感染患者的数据。58%男性,平均年龄为35.7±5.7岁。与单一感染的患者相比，HIV-1和HTLV-1合并感染的患者更可能具有更短的生存期和更快的死亡或死亡率进展。合并感染的CD4细胞计数较高，使用ART的可能性较小。此外,鱼鳞病等疾病的发病率较高(22.2vs.6.8%），sc疮（18.6vs.0%)，念珠菌病（42vs.12%），网虫病（15.4vs.2％）和脑病等神经系统表现，合并感染患者中周围神经病变和HAM/TSP的报告频率更高.
HIV-1和HTLV-1共感染以及HIV-1和HTLV-1/2三重共感染与较短的生存期有关，死亡率更高，更快的死亡进程，而合并感染HIV-1/HTLV-2似乎与更长的生存期有中性关联，艾滋病进展较慢，和较低的死亡率。现有证据表明，迫切需要预防和控制措施，包括筛查,诊断,以及HIV-1和HTLV-1/2共感染患者的治疗。在HTLV感染流行地区，HIV感染者的检测和治疗策略是强制性的，避免合并感染患者延迟治疗和死亡的风险。
https://www。crd.约克。AC.英国/普华永道/，标识符：CRD42021279062。
